secwatch.observer — SEC 8-K summary
======================================

Issuer:     Surrozen, Inc./DE (SRZN)
CIK:        0001824893
Form:       8-K
Filed at:   2025-05-09T23:59:59+00:00
Accession:  0000950170-25-068011
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Surrozen Q1 net loss $27M, cash $101.6M; discontinues SZN-043, pivots to ophthalmology
--------------------------------------------------------------------------------

- Net loss of $27.0M ($7.43 per share) vs $8.8M ($4.24 per share) in Q1 2024; R&D expenses $6.6M.
- Cash increased to $101.6M from $34.6M at year-end 2024, boosted by $76.4M from first tranche of $175M private placement.
- Discontinued SZN-043 for severe alcohol-associated hepatitis due to insufficient Phase 1b benefit; shifted focus to ophthalmology.
- Expects to file IND for lead candidate SZN-8141 in 2026; FDA clearance triggers $98.6M tranche to fund operations.
- Research service revenue $1.0M from TCGFB collaboration; other income $38.0M from non-cash warrant valuation changes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824893/000095017025068011/0000950170-25-068011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824893/000095017025068011/srzn-20250509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-068011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer